Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6361 to 6375 of 9009 results

  1. Have your say on NICE's adoption of the new EQ-5D-5L value set

    We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of life.

  2. 500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause

    A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable.

  3. NICE recommends life changing technology is rolled out to people with type 1 diabetes

    Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.

  4. Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care

    Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 babies' hearing so far with potential to prevent hearing loss in 200 babies annually.

  5. International collaboration provides new guidance on the use of surrogate endpoints in cost-effectiveness analysis

    Recommendations will help organisations that evaluate new drugs establish whether their use will result in longer-term benefits for patients

  6. Patients to get new medicines up to 6 months sooner

    A new aligned pathway between NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) will help bring medicines to patients faster.

  7. Improving outcomes in haemato-oncology cancer (CSG3)

    This guidance has been updated and replaced by NICE guideline NG47.

  8. Improving outcomes in colorectal cancer (CSG5)

    This guidance has been updated and replaced by NICE guideline NG151.

  9. Diabetes: statins for primary prevention of CVD (T2DM and 10% risk) (IND182)

    This guidance has been updated and replaced by NICE indicator 274.

  10. Atrial fibrillation: pulse rhythm assessment in people at risk (IND168)

    This indicator has been withdrawn following National Screening Committee recommendations and ongoing research.

  11. Weight management: BMI calculation in preceding 5 years (IND167)

    This indicator has been withdrawn following discussions with the National Screening Committee.

  12. Diabetes: T1DM and statins (IND166)

    This guidance has been updated and replaced by NICE indicator 277.

  13. Weight management: BMI recording (long-term conditions) (IND151)

    This indicator has been updated and replaced by NICE indicator 320.

  14. Diabetes: blood pressure (without moderate or severe frailty) (IND236)

    This indicator has been updated and replaced by NICE indicator 249.